Revenue
2019
2020
2021
2022
2023
2024
2025
Eton Pharmaceuticals, Inc. (ETON)
Price$55.62Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $80.0M | $39.0M | $31.6M | $21.3M | $21.8M | $39,000 | $959,000 | — |
| Gross profit | $42.7M | $23.4M | $21.1M | $14.3M | $19.0M | −$397,000 | $506,000 | — |
| Gross margin | 53.46% | 60.01% | 66.56% | 67.38% | 87.05% | −1,017.95% | 52.76% | — |
| Research & development | $7.8M | $3.3M | $3.3M | $4.0M | $6.2M | $14.1M | $11.6M | $5.6M |
| Operating expenses | $43.6M | $26.0M | $22.3M | $22.6M | $20.5M | $26.7M | $19.1M | $10.3M |
| Operating income | −$844,000 | −$2.6M | −$1.2M | −$8.3M | −$1.5M | −$27.1M | −$18.6M | −$10.3M |
| Operating margin | −1.06% | −6.66% | −3.77% | −38.87% | −6.85% | −69,515.38% | −1,939.62% | — |
| EBITDA | $3.2M | −$1.5M | −$291,000 | −$8.2M | −$1.3M | −$26.8M | −$18.3M | −$10.3M |
| EBITDA margin | 4.00% | −3.72% | −0.92% | −38.56% | −6.14% | −68,625.64% | −1,910.11% | — |
| Net income | −$4.6M | −$3.8M | −$936,000 | −$9.0M | −$2.0M | −$28.0M | −$18.3M | −$12.7M |
| Net profit margin | −5.75% | −9.80% | −2.96% | −42.45% | −8.95% | −71,717.95% | −1,910.32% | — |
| Basic EPSper basic share | -$0.17 | -$0.15 | -$0.04 | -$0.36 | -$0.08 | -$1.33 | -$1.03 | -$5.80 |
| Diluted EPSper diluted share | -$0.17 | -$0.15 | -$0.04 | -$0.36 | -$0.08 | -$1.33 | -$1.03 | -$5.80 |
Owners
Reported shareholders
10.11%of listed shares
Opaleye Management Inc.2.86M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Opaleye Management Inc. | 10.11%2.86M shares |
Nantahala Capital Management, LLC | 8.31%2.35M shares |
EcoR1 Capital, LLC | 7.68%2.17M shares |
BlackRock, Inc. | 6.70%1.9M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.45%976.57K shares |
BRYNJELSEN SEAN | ≈2.95%833.69K shares |
MORGAN STANLEY | 2.71%767.97K shares |
STATE STREET CORP | 2.48%701.79K shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.31%652.3K shares |
OBERWEIS ASSET MANAGEMENT INC/ | 1.77%501.6K shares |
National Philanthropic Trust | 1.74%492.11K shares |
Westside Investment Management, Inc. | 1.52%431.16K shares |
Pillsbury Lake Capital LLC | 1.37%387.16K shares |
Nuveen, LLC | 1.33%375.71K shares |
BNP PARIBAS FINANCIAL MARKETS | 1.14%322.47K shares |
Woodline Partners LP | 1.10%310.88K shares |
THOMPSON SIEGEL & WALMSLEY LLC | 1.05%297.23K shares |
NORTHERN TRUST CORP | 0.90%255.85K shares |
MARSHALL WACE, LLP | 0.88%249.18K shares |
RIEDEL NORBERT G | ≈0.79%224.3K shares |
Percentages use 28.29M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 17, 2026Form 4 | Adams Jennifer McKieDirector | SellCommon Stock | 50.0K | $32.48 | $1.62M | 0 |
| May 28, 2026Form 4 | BRYNJELSEN SEANPresident & CEO | SellCommon Stock | 148 | $32.67 | $4.8K | 833.7K |
| May 28, 2026Form 4 | BRYNJELSEN SEANPresident & CEO | SellCommon Stock | 119.9K | $31.88 | $3.82M | 833.8K |
| May 27, 2026Form 4 | Krempa DavidChief Business Officer | SellCommon Stock | 19.7K | $31.47 | $619.3K | 25.2K |
| May 26, 2026Form 4 | Krempa DavidChief Business Officer | SellCommon Stock | 37.5K | $31.49 | $1.18M | 25.2K |
Community posts
Eton begins U.S. commercialization of IMPAVIDO under exclusive rights
Eton Pharmaceuticals ($ETON) launched IMPAVIDO capsules through its U.S. rare-disease commercial organization after obtaining exclusive domestic commercialization rights. The medicine contains miltefosine and treats specified forms of leish ...
